Assessment of health-related quality of life in patients receiving stem cell therapy for end-stage liver disease: An Egyptian study

Stem Cell Research and Therapy

Volumn 3, Issue 6, 2012, Pages

  Salama, Hosny ^a   Zekri, Abdel Rahamn N ^b   Ahmed, Rasha ^a   Medhat, Iman ^a   Abdallah, El Sayed ^a   Darwish, Tarneem ^a   Ahmed, Ola S ^b   Bahnassy, Abeer ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ADULT; ARTICLE; ASCITES; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; BIOLOGICAL THERAPY; BLOOD; CYTOLOGY; LIVER FAILURE; MIDDLE AGED; MORTALITY; PSYCHOLOGY; STEM CELL; SURVIVAL RATE; TIME;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CELL- AND TISSUE-BASED THERAPY; FEMALE; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; STEM CELL TRANSPLANTATION; STEM CELLS; SURVIVAL RATE; TIME FACTORS;

EID: 84871907184     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt140     Document Type: Article

References (18)

1. Realities and prospects for the use of cell technologies for the treatment of chronic diffuse liver diseases. Lazebnik LB, Golovanova EV, Slupskaia VA, Trubitsina IE, Kniazev OV, Shaposhnikova NA, Eksp Klin Gastroenterol 2011 6 3 10 22168071
2. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Mittermaier C, Dejaco C, Waldhoer T, Psychosom Med 2004 66 79 84 10.1097/01.PSY.0000106907.24881.F2 14747641 (Pubitemid 38146536)
3. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. Kondo Y, Yoshida H, Tateishi R, J Gastroentrol Hepatol 2007 22 197 203 10.1111/j.1440-1746.2006.04456.x (Pubitemid 46181349)
4. Is quality of life determined by expectations of experience? Carr AJ, Gibson BA, Robinson PG, BMJ 2001 322 1240 1243 10.1136/bmj.322.7296.1240 11358783 (Pubitemid 32453083)
5. Efficacy of autologus hematopoietic stem cell transplantation in 57 patients with end stage chronic liver disease. Salama H, Zekri A, Zern M, Cell Transplant 2010 19 1475 1486 10.3727/096368910X514314 20587151
6. Quality of life of Egyptian donors after living-related liver transplantation. El-Serafy M, Kassem A, Alansary A, Omar A, Yosry A, Esmat G, Kamel R, Refaat S, Doss W, Zayed N, El-Mallahy T, Zakaria S, Arab J Gastroenterol 2009 10 21 24 10.1016/j.ajg.2009.03.004
7. Health related quality of life in Egyptian liver transplant recipient. Sally AA, Mahasen M, Ashraf O, Nagla ZM, Al Sahar M, MD thesis, Cairo University 2011
8. Stem cell transplantation in patients with advanced liver cirrhosis: quality of life assessment. Nouman MG, Hala GM, Mona AA, Ehab EM, UEGW Vienna 2008 76 469 477
9. Tissue engineering and reparative medicine. Sipe J, Kelley C, McNicol L, Ann N Y Acad Sci 2002 961 1 9 10.1111/j.1749-6632.2002.tb03040.x 12081856 (Pubitemid 34721731)
10. Autologous CD34(+) and CD133(+) stem cells transplantation in patients with end stage liver disease. Salama H, Abdel-Rahman NZ, Ghada MS, World J Gastroenterol 2010 16 5297 5305 10.3748/wjg.v16.i42.5297 21072892
11. Quality of life after lobectomy for adult liver transplantation. Kim-Schluger L, Florman SS, Schiano T, O'Rourke M, Gagliardi R, Drooker M, Emre S, Fishbein TM, Sheiner PA, Schwartz ME, Miller CM, Transplantation 2002 73 1593 1597 10.1097/00007890-200205270-00012 12042645 (Pubitemid 34568671)
12. Donor evaluation, donor risks, donor outcome, and donor quality of life in adult-to-adult living donor liver transplantation. Pascher A, Sauter IM, Walter M, Lopez-Haeninnen E, Theruvath T, Spinelli A, Neuhaus R, Settmacher U, Mueller AR, Steinmueller T, Neuhaus P, Liver Transplant 2002 8 829 837 10.1053/jlts.2002.34896 (Pubitemid 35012295)
13. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R, Arch Iran Med 2007 10 459 466 17903050 (Pubitemid 350001896)
14. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M'Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA, Stem Cells 2006 24 1822 1830 10.1634/stemcells.2005-0629 16556705 (Pubitemid 44474196)
15. Improved liver function in liver cirrhosis patients after autologous bone marrow cell infusion therapy. Terai S, Ishikawa T, Omori K, Stem Cells 2006 24 2292 2298 10.1634/stemcells.2005-0542 16778155 (Pubitemid 44527483)
16. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34 cells in patients with chronic liver disease. Levicar N, Pai M, Habib N, Cell Prolif 2008 41 115 125 18181952 (Pubitemid 350295860)
17. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Kim JK, Park YN, Kim JS, Park MS, Paik YH, Seok JY, Chung YE, Kim HO, Kim KS, Ahn SH, Kim DY, Kim MJ, Lee KS, Chon CY, Kim SJ, Terai S, Sakaida I, Han KH, Cell Transplant 2010 19 1237 1246 10.3727/096368910X506863 20525430
18. Understanding and assessing diabetes-specific quality of life. Polonsky WH, Diabetes Spectrum 2010 13 36